This update was written automatically with AI from market data and news wire reports, and published without review by a person.
Key Takeaways
- CoreWeave expects $9 billion in customer prepayments in Q4 2026 as it pivots away from unsecured debt to fund a massive $132.5 billion contract backlog.
- Pfizer (PFE) entered a licensing deal with Starna Therapeutics worth up to $2.63 billion to develop in vivo CAR-T therapies for autoimmune diseases.
- The United Kingdom is reportedly resisting European Union pressure to align tariffs on Chinese goods, prioritizing independent trade policy over "Made in Europe" subsidies.
- Chinese President Xi Jinping called for the APEC region to become a "pacesetter for innovation," emphasizing cooperation in Artificial Intelligence and the digital economy.
CoreWeave Shifts Strategy to Prepayments Amid AI Boom
AI infrastructure provider CoreWeave (CRWV) is overhauling its financing model, moving toward customer-funded growth to avoid high-yield debt markets. The company expects to collect approximately $9 billion in customer prepayments and deposits during the fourth quarter of 2026. This capital influx is critical as the company manages a $132.5 billion revenue backlog and projects annual capital expenditures between $37 billion and $39 billion.
Despite reporting $3.66 billion in Q3 revenue—a 168% year-over-year increase—CoreWeave posted a $709 million net loss due to $846 million in quarterly interest expenses. CEO Michael Intrator stated the company will not use unsecured debt at current yields, opting instead for loans backed by specific customer contracts. Market demand remains high, with short-term capacity reportedly selling for over $40 million per megawatt annually.
Pfizer Expands Pipeline with $2.6B CAR-T Agreement
Pfizer (PFE) has secured an exclusive licensing agreement with Starna Therapeutics to develop next-generation treatments for autoimmune diseases. Under the terms, Starna will receive an upfront payment of $330 million and is eligible for up to $2.3 billion in additional milestone payments. The deal focuses on three pre-IND in vivo CAR-T programs, a promising technology that aims to reprogram immune cells directly within the patient's body.
The agreement grants Pfizer exclusive rights outside of Greater China, though the pharmaceutical giant holds options to expand the territory later. This move signals Pfizer’s aggressive expansion into Inflammation & Immunology, leveraging Starna's proprietary lipid nanoparticle (LNP) delivery platform. Pfizer plans to utilize its U.S. facilities for initial clinical trial manufacturing.
UK-EU Trade Friction Over Chinese Tariffs
The United Kingdom is set to resist a request from the European Union to match its tariffs on Chinese imports, according to a report from the Financial Times. The disagreement comes ahead of a high-stakes summit on Friday, where the two sides hope to establish a "common prosperity and economic security space." Brussels has urged London to align its trade defenses, particularly on Chinese electric vehicles, to prevent the UK from becoming a "back door" for cheap imports.
British officials, including Business Secretary Jonathan Reynolds, have maintained that trade measures must be based on independent UK economic interests. This divergence may complicate the UK's efforts to access the EU's "Made in Europe" industrial subsidies and contracts. While the UK seeks a closer strategic partnership, it remains wary of potential trade reprisals from Beijing.
Xi Jinping Pushes for Innovation at APEC Summit
Speaking at the APEC CEO Summit in Shenzhen, Chinese President Xi Jinping urged member economies to explore new paths for innovation-driven growth. Xi highlighted that the Asia-Pacific region should act as a "fertile ground for scientific breakthroughs," specifically calling for deeper cooperation in Artificial Intelligence and the green energy transition.
The President emphasized that "unilateralism and protectionism" are major hurdles to global growth and advocated for the elimination of trade and investment barriers. The summit, hosted in China for the first time since 2014, serves as a backdrop for high-level bilateral meetings, including an anticipated session between Xi and U.S. leadership to discuss regional economic integration.
Automated market updates written with AI from market data and news wire reports, published without human review.